PD-L1 antibody drug study for advanced lung and head/neck cancers
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced (metastatic or unresectable) solid tumor that fits one of the study cancer types
- Your cancer must have progressed after approved treatment or you cannot take/keep taking it
- You must have had past PD-L1 testing, and your results must meet the study threshold (at least 1 on the right scoring method)
- Your cancer must have measurable disease that can be tracked on scans
- Your overall functioning must be good (ECOG 0 or 1)
- You must not have certain recent treatments or brain/spread-in-the-spine complications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a radioactive medicine (177Lu-anti-PD-L1 sdAb) that delivers radiation to cancer cells with PD-L1 protein, which is found on some solid tumors. It is for people whose cancer has spread or come back after standard treatments.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy as a first treatment for people with advanced non-squamous non-small cell lung cancer that does not have the PD-L1 protein. The goal is to see if this combination works better than standard treatments.
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
This trial tests whether using two immunotherapy drugs together works better than a single drug for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. The study aims to find a more effective treatment for this specific type of lung cancer.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.